1 citations
,
December 2024 in “Journal of Orthopaedic Research®” Aromoline and DRD4 are potential targets for osteoarthritis treatment.
12 citations
,
June 2019 in “Psychoneuroendocrinology” Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
November 2017 in “Reactions Weekly” Testosterone undecanoate caused hair loss; finasteride improved it but caused stomach issues for one patient.
22 citations
,
August 1999 in “Experimental Dermatology” Certain drugs can cause early hair growth in mice by affecting the nerves.
Men with early-onset hair loss are less responsive to bromocriptine's heart and metabolism benefits.
12 citations
,
December 2012 in “Current Drug Targets” The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
10 citations
,
October 2006 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are easier to use and target specific tissues to reduce side effects.
10 citations
,
March 2016 in “Journal of The American Academy of Dermatology” Antiandrogenic drugs could be a good treatment option for frontal fibrosing alopecia.
24 citations
,
October 1995 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” The nafarelin test can reliably distinguish between gonadotropin deficiency and delayed puberty in teenage boys.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
August 2008 in “European Neuropsychopharmacology” RY-023, a specific drug, can improve early stage memory learning without affecting general activity in rats, but it's less effective for later learning stages and doesn't impact memory recall.
June 2023 in “Clinica Chimica Acta” Finasteride and dutasteride effectively reduce DHT in hair, which may help evaluate their treatment success for hair loss.
November 2011 in “Nature Clinical Practice Urology” 5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
8 citations
,
January 2011 in “Korean Journal of Andrology” The doxazosin plus tamsulosin combination improved symptoms effectively with fewer side effects.
12 citations
,
May 2020 in “Actas Dermo-Sifiliográficas” Dutasteride injections may be a future option for treating hair loss.
May 2025 in “Texas Digital Library (University of Texas)” Extracellular ATP promotes growth, while adenosine inhibits it in Arabidopsis plants.
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
47 citations
,
November 1982 in “Journal of Cardiovascular Pharmacology” Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
February 2016 in “PubMed” Properly administered testosterone therapy is safe and effective but often not covered by insurance.
164 citations
,
January 2003 in “Drugs” 10 citations
,
July 2011 in “Archives of Pharmacal Research” November 2007 in “Data Archiving and Networked Services (DANS)” Androgen receptors play a key role in male development and prostate cancer, with treatments targeting androgen action.
April 2011 in “Cancer Research” 20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
1 citations
,
April 2017 in “Drugs & Therapy Perspectives” Use antiandrogens and other treatments for hair loss.